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ABSTRACT
Introduction Cost-related non-adherence to medicines 
is common in low-income, middle-income and high-
income countries such as Canada. Medicine non-
adherence is associated with poor health outcomes 
and increased mortality. This randomised trial will 
test the impact of a carefully selected list of essential 
medicines at no charge (compared with usual medicine 
access) in primary care patients reporting cost-related 
non-adherence.
Methods and analysis This is an open-label, parallel 
two-arm, superiority, individually randomised controlled 
trial conducted in three primary care sites (one urban, 
two rural) in Ontario, Canada, that was codesigned by a 
community guidance panel. Adult patients (≥18 years) 
who report cost-related non-adherence to medicines 
are eligible to participate in the study. Participants will 
be randomised to receive free and convenient access 
to a carefully selected list of 125 essential medicines 
(based on the WHO’s Model List of Essential Medicines) 
or usual means of medicine access. Care for patients in 
both groups will otherwise be unchanged. The primary 
outcome of this trial is adherence to appropriately 
prescribed medicines. Secondary outcomes include 
medicine adherence, appropriate prescribing, blood 
pressure, haemoglobin A1c, low-density lipoprotein 
cholesterol, patient-oriented outcomes and healthcare 
costs. All participants will be followed for at least 12 
months.
Ethics and dissemination Ethics approval was obtained 
in all three participating sites. Results of the main trial and 
secondary outcomes will be submitted for publication in a 
peer-reviewed journal and discussed with members of the 
public and decision makers.
Trial registration number NCT02744963.
InTroducTIon
Medicine non-adherence rates range between 
30% and 40% for chronic disease treat-
ments in low-income, middle-income and 
high-income countries.1 The cost of medi-
cines is one of the most important drivers of 
non-adherence according to observational 
studies and qualitative studies.2–4 Non-ad-
herence to medicines can lead to substantial 
worsening of health outcomes as well as 
increased healthcare expenditure.5 For US 
Strengths and limitations of this study
 ► The intervention in this randomised controlled trial 
combines three elements: free medicine access, a 
carefully selected list of essential medicines, and 
centralised distribution and delivery of prescription 
medicines by a pharmacist who has access to the 
electronic health record.
 ► Medicine adherence will be measured using a 
combination of methods, including self-reported 
questionnaires, chart reviews and electronic 
monitoring.
 ► The trial participants will be recruited from primary 
care practices so individuals who are not already 
connected to a primary care provider will not be 
included.
 ► This trial will not be able to determine the 
contributions of the various components of the 
intervention towards any effects measured or the 
long-term effects of medicine access, including 
effects on hard outcomes.
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Medicare beneficiaries, a review of 47 studies found that 
greater drug coverage and decreased patient cost sharing 
improved medicine adherence.6 Providing medicines 
at no charge to patients reporting cost-related non-ad-
herence may improve medicine adherence and clinical 
outcomes, particularly for the elderly, vulnerable individ-
uals and those with chronic diseases.6 7 There is limited 
literature that evaluates the impact on adherence of 
providing medicines at no charge.7 In the Post-Myocar-
dial Infarction Free Rx Event and Economic Evaluation 
(MI FREEE) trial, which was conducted in a highly 
selected group of post-myocardial infarction  patients and 
only involved antiplatelet, beta-blockers, ACE inhibitors, 
angiotensin receptor blockers and statins, the absolute 
adherence for all patients in the full coverage interven-
tion group (43.9%±33.7%) was 5.4% (adjusted, 95% CI 
3.6% to 7.2%; p<0.001) higher compared with the usual 
coverage control group (38.9%±32.7%).7 There was no 
significant improvement in the primary composite clin-
ical outcome of the rate of first readmission for a major 
vascular event or coronary revascularisation (17.6 inter-
vention vs 18.8 control; HR, 0.93; 95% CI 0.82 to 1.04; 
p=0.21).7 However, secondary clinical outcomes of rates 
of total major vascular events or revascularisation (21.5 
intervention vs 23.3 control; HR, 0.89; 95% CI 0.90 to 
0.99; p=0.03) and rates of first major vascular event 
(11.0 intervention vs 12.8 control; HR, 0.86; 95% CI 0.74 
to 0.99; p=0.03) were significantly reduced in the full 
coverage group.7 In other published trials that provided 
access to medicines for free, the intervention differed 
from the control condition in ways other than free access 
to medicines, and participants in the control groups had 
access to medicines without charge.8 9
Adherence to inappropriately prescribed medicines 
can also harm people. Using 52 indicators, the preva-
lence of potentially inappropriate prescribing in the UK 
in 2007 was 27%.10 More than 50% of US senior Medicare 
beneficiaries being treated with a prescription medicine 
received at least one potentially inappropriate medicine 
during a calendar year.11 There is evidence that restricted 
formularies improve prescribing practice and reduce 
inappropriate prescribing by directing prescribing based 
on efficacy, safety and economy.12–14 Other jurisdictions 
have developed short lists that include only essential 
medicines. Sweden’s ‘Wise List’ of approximately 200 
medicines and the UK’s regional short lists are examples 
of successful cost-effective, evidence-based formularies 
in high-income countries.15 16 There are no published 
randomised controlled trials (RCTs) or systematic 
reviews that evaluate the impact of limited formularies on 
prescribing appropriateness in a primary care setting.
The WHO recommends that nations develop a list of 
essential medicines ‘that satisfy the priority health care 
needs of the population’.17 Canada is an ideal setting to 
study the effects of providing people with free access to an 
essential list of medicines because (1) cost-related non-ad-
herence is common, (2) clinicians currently prescribe a 
large number of different medicines and (3) healthcare 
services such as seeing a doctor are generally publicly 
funded. In Canada, physician visits, hospitalisations, emer-
gency department visits and some home care services are 
publicly insured, but the cost of medicines are only publicly 
insured for special populations (such as people receiving 
social assistance and low-income seniors). Canada is the 
only developed nation with universal healthcare coverage 
that does not include prescription medicines. The rate 
of cost-related non-adherence is 9.6% (95% CI 8.5% to 
10.6%) and higher for those with low income who also 
have a shorter life expectancy.18 Approximately one-third 
(31%) of prescriptions in the province of Quebec are not 
filled, and the prevalence of non-adherence is greater for 
more expensive medicines.19 Pharmaceutical coverage 
in Canada is a ‘patchwork’ of public and private drug 
plans that leaves many Canadians with inadequate or no 
medicine coverage.20 Public drug formularies in Canada 
contain thousands of products (eg, there are more than 
4000 medicines on the public formulary in Ontario). In 
2013, 37% of Canadian seniors received one or more 
prescriptions for potentially inappropriate medicines.21 
An estimated 17% of hospitalisations in Canada could be 
prevented if prescription drugs were used more appro-
priately.22 The intervention in this study could improve 
adherence and appropriate prescribing and ultimately 
improve health outcomes.
AIms And objecTIves
The aim of this study is to evaluate the effect of providing 
patients recruited at primary care clinics with free and 
convenient access to a carefully selected set of essen-
tial medicines on appropriate medicine adherence and 
surrogate health outcomes:
Population— adult primary care patients who report 
cost-related non-adherence to medicines.
Intervention— free and convenient access to a carefully 
selected set of essential medicines with otherwise usual 
care (n=392).
Control— usual access to medicines and usual care 
(n=392).
Outcomes— primary: appropriate adherence to medi-
cines over 12 months. Secondary: appropriate prescribing, 
medicine adherence, haemoglobin A1c (HbA1c) levels 
(in patients with diabetes); blood pressure (in patients 
with hypertension); cholesterol (in patients with dyslip-
idemia); patient-oriented outcomes; and average per 
person medicine costs.
Participants in both groups will be treated the same 
except for the intervention.
meThods And AnAlysIs
design
This will be an open-label, parallel two-arm, superiority, 
individually randomised controlled trial with 1:1 allo-
cation. The trial is open label as participants are told 
their allocation group immediately after randomisation. 
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Figure 1 summarises the design and timeline of the 
trial, and specific trial details are described below.
setting
Carefully seLected and Easily Accessible at No Charge 
Medicines (CLEAN Meds) is a multicentre RCT. The 
study will be conducted in one urban family practice affili-
ated with St Michael’s Hospital in Toronto (population of 
Toronto 2.6 million; 40 000 rostered patients in practice) 
and two rural family practices in Ontario: Huron Shores 
Family Health Team in Blind River, Ontario (population 
3500) and the Municipality of Assiginack Family Health 
Team in Manitoulin Island, Ontario (population 12 000). 
All three sites use the same electronic medical record. 
These sites were selected in order to assess the interven-
tion in both urban and rural settings.
eligibility criteria
Patients aged 18 years or older and self-report medi-
cine non-adherence in the last 12 months are eligible 
for inclusion in the study. The question used to identify 
non-adherence will use phrasing chosen in the Canadian 
Community Health Survey and similar surveys in other 
countries: ‘In the last twelve months, did you not fill a 
prescription or do anything to make a prescription last 
longer because of the cost?’18 Exclusion criteria include 
family member(s) living at the same address of patients 
already enrolled, and joined the family practice within 
the last 6 months. We will not exclude patients who are 
eligible for public medicine insurance but who do not 
have such coverage (eg, patients who have lost or cannot 
access their benefit card). We will not exclude patients 
with public or private medicine insurance as long as 
they report cost-related non-adherence. Private insur-
ance often requires some out-of-pocket expenses, and in 
Canada 7% of those with prescription medicine insurance 
(usually through employment) still report cost-related 
non-adherence.18 Individuals who have private insurance 
and not experiencing cost-related barriers to medicine 
adherence will not be eligible for inclusion in the study.
randomisation and patient recruitment
Patients will be recruited during routine primary care 
visits. Clinicians will briefly inform patients about the 
study, and interested patients will be provided with 
more information by research assistants. Research assis-
tants across three sites will be responsible for patient 
enrolment. Patients who meet the eligibility criteria 
are centrally randomised into two groups: intervention 
group, where patients will receive free and convenient 
access to a carefully selected list of essential medicines, 
or the control group. All participants will receive usual 
care. Each participant will be assigned a unique patient 
study number. Randomisation will be concealed using a 
web-based tool hosted by the Applied Health Research 
Centre (AHRC) at the Li Ka Shing Knowledge Institute 
of St Michael’s Hospital, and can be accessed through 
the electronic case report forms, which will be available 
through the REDCap application. The randomisation 
method was designed in R and is stratified by site using 
permuted blocks of varying sizes. Subsequent to the initial 
automated allocation, a second automated allocation will 
be performed, where every seventh patient enrolled into 
each arm across all sites (no site stratification) will receive 
an electronic monitoring device to measure adherence. 
The electronic monitoring device is based on the order 
of enrolment at each site. Research investigators and 
analysts will be blinded to treatment allocation to reduce 
ascertainment bias. Given the interventions, patients, 
clinicians and pharmacists will not be blinded to treat-
ment allocation.
Intervention arm
Patients in the intervention arm will receive free and 
convenient access to a list of essential medicines (see 
http://www. cleanmeds. ca for a list of medicines). Both 
Figure 1 The design and timeline of the trial. BP, blood pressure; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein 
cholesterol.; EMR, electronic medical record
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prescribing clinicians and intervention patients will have 
access to the list of essential medicines. Patients may still 
be prescribed other medicines not found on the essential 
list and access them in the usual way (eg, by paying for 
them).
The list of essential medicines was adapted from the 
2013 WHO Model List of Essential Medicines23 using a 
four-step interdisciplinary, clinical peer review process. 
Additional medicines were added or removed from 
the list based on clinician suggestions, pharmaceutical 
industry suggestions and retrospective prescribing data.24 
A panel of clinician-scientists who are free of financial 
conflicts of interest convenes every 3 months to evaluate 
the evidence and votes on recommended changes to the 
list using a modified nominal group technique.25 26 For 
medicines removed from the list throughout the duration 
of the study, patients who were initially prescribed these 
medicines on enrolment will remain on these medicines.
Medicine dispensing for the essential medicines will 
primarily be through the mail. A supply of medicines 
that are needed for acute care (eg, antibiotics) will be 
stocked at each clinic study site and available for on-site 
dispensing by the clinician, and dispensing records will be 
kept to prevent contamination. For all other medicines 
covered by the list, the research pharmacist who will have 
direct access to patient electronic medical records and 
prescriptions will dispense these medicines as prescribed. 
Medicines can be delivered to a study participant within 
the expected geographical regions in Ontario within 
1 day. Controlled substances (eg, opioids, sedatives and 
stimulants) will not be included in the intervention for 
safety reasons, and patients will access these medicines in 
the usual fashion and not through the research study.
After shipment, a pharmacist who will have access 
to interpretation services in 200 languages will call to 
counsel patients about their medicines. Patients without 
a permanent home address may choose an alternate 
delivery address (eg, the clinic or a support centre). 
Potential prescribers outside of the study sites (eg, urgent 
care providers or secondary care providers) will be faxed 
a letter with the list of essential medicines, and patients 
will be provided with a card with information about the 
list that can be shared with other providers. Both forms of 
communication will include contact information to reach 
the research pharmacist. The control group will receive 
standard care with their usual access to medicines and 
dispensing.
control arm
Participants allocated to the control arm will have their 
usual access to medicines and usual care.
outcome measures
Primary outcome measure
The primary outcome is adherence to appropriately 
prescribed medicines and will be determined at 12 
months by assessing the percentage of prescriptions that 
are both (1) appropriate based on explicit criteria27 and 
(2) taken as prescribed or adhered to for greater than 
80% of doses.
We will use a combination of validated methods for 
assessing medicine adherence, which requires the assess-
ment of both adherence and appropriateness.28 We will 
employ questionnaires, chart reviews and electronic moni-
toring as recommended and used in previous trials.29 The 
eight-item Morisky Medicine Adherence Scale (MMAS-8) 
will be completed by patients over the telephone or during 
a regular scheduled clinic visit between 9 and 12 months 
to determine the proportion of missed doses.30 Taking 
into consideration the number of expected medicine 
doses, self-reported adherence will be defined as greater 
than 80% (eg, one or none missed doses in 1 week for 
a medicine taken once a day). While questionnaires are 
prone to recall bias,28 because of anonymity, they are not 
as susceptible to social desirability bias as interviews,28 29 
and do not sustain a drop in completion rates like diary 
reports.31
Electronic medical record (EMR) chart reviews will 
also be conducted at the end of the study to identify 
issue dates for prescriptions and determine if chron-
ic-use medicines are reordered when expected in a 
blinded fashion. Prescriptions written within 18 days of 
the expected renewal date (20% of typical renewal period 
of 90 days) will be classified as adherent. While suscep-
tible to pill dumping, like other objective measures such 
as pill counts, EMR reviews do not depend on recall.28 
Electronic monitoring devices are considered by many 
researchers as the best available method for measuring 
adherence.32 These instruments passively record each 
time a research participant opens the pill bottle. Given 
the high cost of devices, only a small subset of patients 
in the study (112 participants, half from each treatment 
group) will receive them. Adherence will be defined as 
bottle openings to access medicines greater than 80% of 
the times expected. These data will be collected over the 
period of 12 months for chronic disease medicines.
While self-reporting tends to overestimate adherence,28 
electronic monitoring is prone to underestimation.32 
The combination of three measures will better approx-
imate adherence and will be more rigorous than single 
measures used in previous trials.7–9
Adherence will be treated as a dichotomous variable. 
Participants deemed non-adherent by any of the three 
methods will be classified as non-adherent for the primary 
analysis. Since we will assume the lowest of the three 
possible adherence measures, we will not overestimate 
adherence. If data for all three measures are missing, we 
will assume non-adherence. We will also report adherence 
rates by each of the three measures for the intervention 
and control groups. Prescriptions for medicines intended 
to be taken on an ‘as needed’ basis (eg, analgesics, salbu-
tamol) will be excluded from the adherence analysis.
Blinded assessors with access to patient EMR including 
clinician notes will assess prescribing appropriateness. 
Assessors will review all prescriptions written to patients 
in control and intervention arms using independently 
 5Persaud N, et al. BMJ Open 2017;7:e015686. doi:10.1136/bmjopen-2016-015686
Open Access
developed explicit patient-level prescribing appropri-
ateness indicators. We will either use an existing set of 
appropriateness indicators33 or one based on an ongoing 
systematic review.34 The quality prescribing indicators 
relate to the management of chronic diseases such as 
hypertension, diabetes and asthma in a primary care 
setting.33 Prescribing appropriateness is a dichotomous 
variable and thus each prescription will be counted as 
appropriate or not appropriate.
Secondary outcome measures
1. proportion (%) of prescriptions that are appropriate
2. proportion (%) of prescriptions that are adhered 
to
3. HbA1c levels in patients with diabetes (adjusted for 
baseline)
4. blood pressure in patients with hypertension 
(adjusted for baseline)
5. low-density lipoprotein (LDL) cholesterol levels in 
patients taking a statin (adjusted for baseline)
6. patient-oriented outcomes
7. healthcare costs including medicine costs.
Patient-oriented outcomes
The community guidance panel developed ‘yes’ or ‘no’ 
questions for study participants that will be asked between 
9 and 12 months. In addition to ‘yes’ or ‘no’ responses, 
we will also transcribe comments.
Patient–doctor relationship
 ► Did you feel your care was better than before the 
study started? (yes or no, and open-ended)
 ► Did you feel your questions or concerns were 
addressed? (yes or no, and open-ended)
 ► Was your interaction with specialists different from 
before the study started? (yes or no, and open-
ended)
Information patients receive about medicines
 ► Did the information about medicines given by the 
pharmacist and the doctor match? (yes or no, and 
comments)
 ► Was it easy to obtain information about the 
medicines? (yes or no, and comments)
 ► Did the information change the way you took 
medicines? (yes or no, and comments)
 ► Did you have unanswered questions about your 
medicines? (yes or no, and comments)
Medicine delivery system
 ► Was the medicine in good condition when you 
received it? (yes or no, and comments)
 ► Did you receive new medicines quickly? (only for 
new medicines) (yes or no, and comments)
 ► Did you receive the medicine before the previous 
prescription ran out? (only for renewals) (yes or no, 
and comments)
Other outcomes
 ► Was it easier to make ends meet at the end of the 
month? (yes or no, and comments)
 ► Do you feel your health improved? (yes or no, and 
comments)
 ► Did you have any medicine side effects? (yes or no, 
and comments)
 ► Did you have fewer healthcare visits? (yes or no, and 
comments)
 ► Is there anything else you would like to say? (yes or 
no, and comments)
For healthcare providers
 ► Ask doctor: Did you feel you had enough time in 
your patient encounters?
 ► Ask doctor: Do you think your patients are getting 
access to the medicines they need?
 ► Ask pharmacist: Was communication with the 
prescriber effective?
 ► Ask pharmacist: Was communication with the 
patient effective?
Other outcomes
Other outcomes that will be measured include the counts 
of healthcare encounters, specifically ambulatory visits, 
emergency department visits, hospital admission, investi-
gations and other healthcare utilisation.
data collection
All patients will be followed for 12 months from the date 
of enrolment. Medicine adherence and health outcomes 
data (blood pressure, HbA1c levels and cholesterol levels) 
will be collected during regularly scheduled appoint-
ments. Surrogate health markers captured in this trial are 
known to be associated with clinically important outcomes 
such as myocardial infarction, stroke and mortality.35–38 
Inappropriate prescribing, prescription records and 
costs will be assessed by retrospective audits of the elec-
tronic medical record. No clinic visits are necessary for 
data collection. There are no differences between the two 
groups in the way data are collected or assessed.
statistical analysis
Patient demographics will be summarised descriptively 
(eg, means and SD or median IQR for continuous vari-
ables, and frequency and percentages for categorical). 
Demographics will be reviewed for clinically important 
imbalances that may be adjusted for in a secondary anal-
ysis.
The primary analysis will be performed using an inten-
tion-to-treat principle. Appropriate adherence will be 
compared using a χ2 test, and the unadjusted treatment 
effect will be expressed as the absolute risk difference with 
95% CI as well as the OR with 95% CI. For the primary 
analysis, a two-sided p value of <0.05 will be used to reject 
the null hypothesis of no difference. Adjusted analyses 
will employ logistic regression, and the adjusted (condi-
tional) treatment effect will be expressed as an OR with 
6 Persaud N, et al. BMJ Open 2017;7:e015686. doi:10.1136/bmjopen-2016-015686
Open Access 
95% CI. We will perform sensitivity analyses to determine 
the effect of missing data. We will not adjust for site as the 
purpose of the study is to estimate the effect of the inter-
vention on the population.
The first two secondary outcomes are binary at the 
level of prescription within patients. This will be aggre-
gated to the patient level and logistic regression will be 
used to compare groups. HbA1C, blood pressure and 
LDL cholesterol are all continuous and measured at 
baseline and 9–12 months. An analysis of covariance 
model will be used (via linear regression) to provide 
the estimates of treatment effect adjusted for baseline 
values. Since these are all secondary analyses that are 
supportive or exploratory, no corrections for multiple 
testing will be applied and only patients with data will 
be included. However the intention-to-treat principle 
will still be followed as patients will remain allocated to 
their randomised groups irrespective of compliance. We 
will also perform a subgroup analysis to determine if the 
effects on medicine adherence and health outcomes 
differ by age and sex.
sample size rationale
This study is powered for the primary outcome of adher-
ence to appropriately prescribed medicines. Based on 
previous studies, we expect 40%–60% of patients in the 
control group will be appropriately adherent.7–9 We 
expect at least 90% of patients in the intervention group 
will be adherent to the intervention in the sense that 
they will agree to take at least one of the medicines (but 
note that adherence to the intervention is different from 
medicine adherence). We believe that a 10% absolute 
improvement in appropriate adherence (in the pres-
ence of non-compliance) is the minimal difference that 
is clinically important. A sample size of 392 per group is 
required to have a power of 80% to detect a 10% absolute 
difference in adherence for any control group adherence 
values between 40% and 60%. At a two-sided type 1 error 
of 0.05, no inflation for dropouts is applied to the sample 
size calculation since dropouts will be considered non-ad-
herent. Based on previous trials, we expect the dropout 
rate to be approximately 5%.7–9
monitoring
Data and Safety Monitoring Board
The Data and Safety Monitoring Board (DSMB) will meet 
every 3 months. The primary purpose of the DSMB will 
be to ensure medicine incidents are properly addressed. 
Each medicine error will be reported to the DSMB 
immediately. The DSMB will make recommendations 
to the research team about how to mitigate the harm 
from the medicine incidents and how to prevent future 
similar errors. The DSMB will have the power to recom-
mend discontinuation of the trial if there is an excess 
of medicine incidents or if identified incidents are not 
appropriately managed.
Adverse events
Monitoring for medicine incidents and adverse drug 
reactions will occur from the point of enrolment into the 
study, and will continue for 3 months after the comple-
tion of the 12-month study period for each participant. 
The risk of medicine incidents will be mitigated by having 
the research pharmacist review the EMR of intervention 
patients before initiating or transitioning to alternate 
treatments. We will provide clinicians with instructions 
about how to manage patients who experience discontin-
uation effects (eg, from antidepressants). Discontinuation 
effects will be reported as medicine adverse effects. Medi-
cine incidents and serious adverse events will be collected 
in the electronic case report form, and each event will be 
reported to the DSMB, who will assess ongoing safety of 
the intervention.
management
The research team will receive trial implementation 
assistance from the AHRC. Study data and patient ques-
tionnaires will be entered and maintained on a secure 
password-protected database developed using REDCap 
(https://www. project- redcap. org/) and will be accessible 
via the internet for data entry purposes. Corrections or 
changes in the data management system will be tracked 
with the retention of the original data and the corrected 
data with the date of data entry and submitting personnel.
We expect enrolment to be complete in 12 months, and 
each participant will be followed for 12 months plus an 
additional 3 months of follow-up for adverse events. So 
the study should be completed approximately 27 months 
after the first patient is enrolled.
Public involvement
The trial intervention and some outcomes were code-
signed by a panel of 11 community members who were 
recruited via canvassing, random digit dialling and 
publicly posting notices. These individuals met with the 
research team monthly starting more than 6 months 
before the study started. These meetings will continue 
during the study.
ethics and dissemination
Ethics approval for the conduct of this study was obtained 
from the St Michael’s Research Ethics Board, the Huron 
Shores Family Health Team Research Ethics Committee 
and the Laurentian University Research Ethics Board. 
Version 3.0, which was dated 18 March 2015, of the 
protocol was approved. Any important protocol modifica-
tions will be made after communication with the research 
ethics boards and will be described in the resulting publi-
cations. Informed consent will be obtained by research 
assistants (see online supplementary appendix 1 consent 
form). Personal health data are maintained in the elec-
tronic health record. All investigators will have access to 
the final trial data set.
There are no restrictions on dissemination of the 
results, and we plan to disseminate the results of the study 
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to participants, healthcare providers and governments. 
We plan to make participant-level data publicly available 
when the results are published in a peer-reviewed journal.
The trial is registered with  clinicaltrials. gov 
NCT02744963.
summAry
The CLEAN Meds trial will be the first randomised 
study to evaluate the impact of providing primary care 
patients with free access to a list of essential medicines 
using a centralised mail-order dispensing method where 
the pharmacist has access to the electronic health record. 
This study is powered to detect differences in important 
clinical outcomes in addition to medicine adherence, 
prescribing appropriateness and healthcare costs. The 
findings may inform public policy decisions around medi-
cine access in Canada and other countries.
Strengths of this study include the fact that a wide range 
of medicines will be provided to patients with different 
needs as would happen if public policy were changed, 
participants are recruited from both urban and rural 
sites, and there are few exclusion criteria or requirements 
on participants. Limitations of the study include the use 
of surrogate health outcomes, the inability to disentangle 
the effects of the components of the intervention, the 
lack of long-term intervention provisions and follow-up, 
insufficient power to detect smaller (<10%) improve-
ments in adherence, and the lengthy informed consent 
form that may discourage some eligible individuals from 
participating.
FeAsIbIlITy
We enrolled 323 participants after 26 weeks.
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